ZA202307212B - Interleukin-18 variants and methods of use - Google Patents
Interleukin-18 variants and methods of useInfo
- Publication number
- ZA202307212B ZA202307212B ZA2023/07212A ZA202307212A ZA202307212B ZA 202307212 B ZA202307212 B ZA 202307212B ZA 2023/07212 A ZA2023/07212 A ZA 2023/07212A ZA 202307212 A ZA202307212 A ZA 202307212A ZA 202307212 B ZA202307212 B ZA 202307212B
- Authority
- ZA
- South Africa
- Prior art keywords
- methods
- interleukin
- variants
- activator
- therapeutic
- Prior art date
Links
- 102000003810 Interleukin-18 Human genes 0.000 title abstract 3
- 108090000171 Interleukin-18 Proteins 0.000 title abstract 3
- 239000012190 activator Substances 0.000 abstract 2
- 230000001225 therapeutic effect Effects 0.000 abstract 2
- 102100035017 Interleukin-18-binding protein Human genes 0.000 abstract 1
- 101710205006 Interleukin-18-binding protein Proteins 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000007781 signaling event Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Toxicology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Developmental Biology & Embryology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762554605P | 2017-09-06 | 2017-09-06 | |
| US201862652279P | 2018-04-03 | 2018-04-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA202307212B true ZA202307212B (en) | 2024-10-30 |
Family
ID=65517760
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2023/07212A ZA202307212B (en) | 2017-09-06 | 2023-07-19 | Interleukin-18 variants and methods of use |
Country Status (13)
| Country | Link |
|---|---|
| US (6) | US20190070262A1 (https=) |
| EP (1) | EP3678681A4 (https=) |
| JP (2) | JP7795181B2 (https=) |
| KR (1) | KR20200066623A (https=) |
| CN (1) | CN111315395A (https=) |
| AU (2) | AU2018330444B2 (https=) |
| BR (1) | BR112020004389A2 (https=) |
| CA (1) | CA3080492A1 (https=) |
| IL (2) | IL305370A (https=) |
| MX (1) | MX2020002542A (https=) |
| SG (1) | SG11202001384TA (https=) |
| WO (1) | WO2019051015A1 (https=) |
| ZA (1) | ZA202307212B (https=) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12029778B2 (en) | 2019-05-13 | 2024-07-09 | Yale University | Interleukin-18 mimics and methods of use |
| MX2022014239A (es) * | 2020-05-12 | 2023-02-09 | Regeneron Pharma | Nuevos agonistas de il10 y metodos para su uso. |
| WO2022038417A2 (en) * | 2020-08-19 | 2022-02-24 | Bright Peak Therapeutics Ag | Modified il-18 polypeptides and uses thereof |
| TW202233657A (zh) * | 2020-11-02 | 2022-09-01 | 美商辛卡Ｉｌ １８公司 | 介白素-18變體及使用方法 |
| CN116848130A (zh) * | 2021-02-10 | 2023-10-03 | 国立大学法人长崎大学 | 新型人白细胞介素-18突变体及其用途 |
| US20230146665A1 (en) | 2021-07-27 | 2023-05-11 | Xencor, Inc. | Il-18-fc fusion proteins |
| JP7849832B2 (ja) | 2021-08-06 | 2026-04-22 | 国立大学法人 長崎大学 | がんの治療剤 |
| WO2023114829A1 (en) * | 2021-12-15 | 2023-06-22 | Genentech, Inc. | Stabilized il-18 polypeptides and uses thereof |
| WO2023118497A1 (en) * | 2021-12-22 | 2023-06-29 | Pieris Pharmaceuticals Gmbh | Novel il-18 variants |
| WO2023161853A1 (en) | 2022-02-23 | 2023-08-31 | Bright Peak Therapeutics Ag | Activatable il-18 polypeptides |
| CA3244053A1 (en) * | 2022-02-23 | 2023-08-31 | Bright Peak Therapeutics Ag | MODIFIED IL-18 POLYPEPTIDES |
| US20230263831A1 (en) * | 2022-02-23 | 2023-08-24 | Fred Hutchinson Cancer Center | Methods for enhancing anti-tumor activity of exhausted t cells |
| JP2025508823A (ja) | 2022-02-23 | 2025-04-10 | ブライト ピーク セラピューティクス エージー | 免疫抗原特異的ｉｌ－１８免疫サイトカイン及びその使用 |
| PE20251671A1 (es) | 2022-03-15 | 2025-06-30 | Compugen Ltd | Anticuerpos antagonistas de il-18bp y su uso en monoterapia y terapia de combinacion en el tratamiento del cancer |
| EP4519678A4 (en) * | 2022-05-05 | 2026-04-15 | Hospital Espanol Auxilio Mutuo De Puerto Rico Inc | TREATMENT METHODS FOR BLADDER CANCER |
| CA3261349A1 (en) * | 2022-08-05 | 2024-02-08 | Fuse Biotherapeutics Inc. | IL-18 FUSING PROTEINS AND IL-18 PRODUCTION PROCESSES |
| WO2024044780A1 (en) * | 2022-08-26 | 2024-02-29 | Sutro Biopharma, Inc. | Interleukin-18 variants and uses thereof |
| JP2025529313A (ja) * | 2022-09-06 | 2025-09-04 | ティージェイ バイオファーマ （シャンハイ） カンパニー， リミテッド | Ｉｌ－１８バリアントポリペプチド |
| US20240209100A1 (en) * | 2022-10-21 | 2024-06-27 | Diagonal Therapeutics Inc. | Heteromeric agonistic antibodies to il-18 receptor |
| US20240166705A1 (en) | 2022-11-07 | 2024-05-23 | Xencor, Inc. | Il18-fc fusion proteins |
| CN118141897A (zh) | 2022-12-07 | 2024-06-07 | 广州威溶特医药科技有限公司 | Dr-18和溶瘤痘苗病毒在制备抗肿瘤药物中的应用 |
| EP4646270A2 (en) * | 2023-01-06 | 2025-11-12 | Alector LLC | Anti-il18 binding protein antibodies and methods of use thereof |
| TW202430560A (zh) * | 2023-01-06 | 2024-08-01 | 美商拉森醫療公司 | 抗ｉｌ－１８ｂｐ抗體 |
| IL321948A (en) | 2023-01-06 | 2025-09-01 | Lassen Therapeutics Inc | Anti-IL-18 BP antibodies |
| AU2024211503A1 (en) * | 2023-01-24 | 2025-07-31 | Msd International Business Gmbh | Methods and compositions for combination therapy |
| CN121666402A (zh) * | 2023-06-09 | 2026-03-13 | 默克专利股份公司 | Il-18模拟物 |
| TW202515608A (zh) | 2023-06-26 | 2025-04-16 | 以色列商坎布根有限公司 | Ｉｌ—１８ｂｐ拮抗抗體及其於癌症治療之單一療法及組合療法的用途 |
| WO2025015103A1 (en) * | 2023-07-10 | 2025-01-16 | The Children's Hospital Of Philadelphia | Methods for modulating activity of il-18 for treatment of cd4+ t cell mediated autoimmunity and immunopathology |
| WO2025041102A1 (en) | 2023-08-23 | 2025-02-27 | Bright Peak Therapeutics Ag | Targeted immune activation with il-18 immunocytokines |
| WO2025041101A1 (en) | 2023-08-23 | 2025-02-27 | Bright Peak Therapeutics Ag | Activatable il-18 immunocytokines and uses thereof |
| US20250188166A1 (en) | 2023-08-23 | 2025-06-12 | Bright Peak Therapeutics Ag | Il-18 polypeptides fused to immune cell antigen specific binding polypeptides and uses thereof |
| AU2024352706A1 (en) | 2023-09-28 | 2026-04-02 | Prokarium Limited | Interleukin 18 variants |
| WO2025085447A1 (en) | 2023-10-17 | 2025-04-24 | Xencor, Inc. | Pd-1 targeted il18-fc fusion proteins |
| CN120093897A (zh) * | 2023-12-04 | 2025-06-06 | 广州威溶特医药科技有限公司 | Dr-18和单纯疱疹病毒在制备抗肿瘤药物中的应用 |
| CN120189493A (zh) | 2023-12-22 | 2025-06-24 | 广州威溶特医药科技有限公司 | Dr-18和m1病毒在制备抗肿瘤药物中的应用 |
| US12134635B1 (en) | 2023-12-29 | 2024-11-05 | Sonnet BioTherapeutics, Inc. | Interleukin 18 (IL-18) variants and fusion proteins comprising same |
| WO2025151273A1 (en) * | 2024-01-08 | 2025-07-17 | Adimab, Llc | Il-18 polypeptides and uses thereof |
| WO2025185694A1 (en) * | 2024-03-06 | 2025-09-12 | TJ Biopharma (Shanghai) Co., Ltd. | Constructs comprising il-18 components and uses thereof |
| WO2025242835A1 (en) | 2024-05-22 | 2025-11-27 | Ose Immunotherapeutics | Molecules comprising masking linkers and uses thereof for the treatment of cancer |
| WO2025251226A1 (en) | 2024-06-05 | 2025-12-11 | Nuwacell Biotechnologies Co., Ltd. | Use of interleukin-21 and interleukin-15 for enhancing serial killing of natural killer cell for cell therapy against target cell |
Family Cites Families (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5595756A (en) | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
| US6713279B1 (en) | 1995-12-07 | 2004-03-30 | Diversa Corporation | Non-stochastic generation of genetic vaccines and enzymes |
| US6479258B1 (en) | 1995-12-07 | 2002-11-12 | Diversa Corporation | Non-stochastic generation of genetic vaccines |
| US6790442B1 (en) | 1996-06-27 | 2004-09-14 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Genomic DNA encoding a polypeptide capable of inducing the production of interferon-γ |
| EP0816499A3 (en) * | 1996-06-27 | 1999-10-27 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Genomic DNA encoding a polypeptide capable of inducing the production of interferon-gamma |
| JP4024366B2 (ja) | 1996-11-29 | 2007-12-19 | 株式会社林原生物化学研究所 | ポリペプチド |
| JP3955352B2 (ja) * | 1997-02-25 | 2007-08-08 | 株式会社林原生物化学研究所 | 破骨細胞形成阻害剤 |
| TWI227136B (en) * | 1998-05-21 | 2005-02-01 | Smithkline Beecham Corp | Novel pharmaceutical composition for the prevention and/or treatment of cancer |
| JP2001266941A (ja) | 2000-03-17 | 2001-09-28 | Sony Corp | ゲル電解質電池の製造方法 |
| AU7516601A (en) * | 2000-06-02 | 2001-12-17 | Susan B Dillon | Methods of treating viral diseases with il-18 and il-18 combinations |
| PL208592B1 (pl) | 2000-06-15 | 2011-05-31 | Smithkline Beecham Corp | Sposób wytwarzania aktywnego ludzkiego polipeptydu IL-18 z ludzkiego polipeptydu prekursora IL-18 |
| US6818444B2 (en) | 2000-08-04 | 2004-11-16 | Heska Corporation | Canine and feline proteins, nucleic acid molecules and uses thereof |
| ATE315647T1 (de) * | 2001-03-08 | 2006-02-15 | Ares Trading Sa | Interleukin -18 mutantenproteine, deren herstellung und verwendung |
| ATE490968T1 (de) | 2001-05-04 | 2010-12-15 | Cornell Res Foundation Inc | Schnell spaltbares sumofusionsprotein- expressionssystem für schwer zu exprimierende proteine |
| AU2002326961A1 (en) | 2001-10-10 | 2003-04-22 | Centocor, Inc. | Nucleic acid vaccines using tumor antigen encoding nucleic acids with cytokine adjuvant encoding nucleic acid |
| WO2003057821A2 (en) | 2001-10-26 | 2003-07-17 | Centocor, Inc. | Mut-il-18 or mut-il-18r proteins, antibodies, compositions, methods and uses |
| US6800479B2 (en) | 2001-12-11 | 2004-10-05 | Samyang Genex Corporation | Recombinant adenoviruses expressing interleukin-18 protein and gene therapy using them |
| US7220576B2 (en) | 2002-01-07 | 2007-05-22 | Lifesensors, Inc. | Methods and compositions for protein expression and purification |
| CA2472477C (en) | 2002-01-07 | 2012-03-20 | Lifesensors, Inc. | Methods and compositions for protein expression and purification |
| US7253260B2 (en) | 2002-04-17 | 2007-08-07 | Smithkline Beecham Corporation | Human IL-18 crystal structure |
| AU2003280017A1 (en) * | 2002-06-27 | 2004-01-19 | Smithkline Beecham Corporation | Methods of treating or preventing ibd with il-18 |
| MXPA05003869A (es) * | 2002-10-08 | 2005-06-22 | Ares Trading Sa | El uso de citocina capaz de enlazarse a la proteina de union a interleucina-18, y de inhibir la actividad de una segunda citocina. |
| ATE459647T1 (de) | 2003-04-15 | 2010-03-15 | Glaxosmithkline Llc | Humane il-18 substitutionsmutanten und deren konjugate |
| US20080076708A1 (en) * | 2003-05-13 | 2008-03-27 | Valter Altarocca | Active Variants of the Il-18 Binding Protein and Medical Uses Thereof |
| AU2004254600A1 (en) | 2003-06-26 | 2005-01-13 | Lifesensors, Inc. | Methods and compositions for enhanced protein expression and purification |
| DE602004031341D1 (de) | 2003-07-21 | 2011-03-24 | Transgene Sa | Multifunktionelle cytokine |
| DK1648931T3 (da) * | 2003-07-21 | 2011-03-07 | Transgene Sa | Multifunktionelle cytokiner |
| WO2005075648A1 (en) * | 2004-01-28 | 2005-08-18 | Gifu University | Interleukin-18 mutant proteins |
| EP1793859B1 (en) | 2004-08-20 | 2009-03-25 | Smithkline Beecham Corporation | Treatment of oral and intestinal mucositis by administering human il-18 |
| US8119369B2 (en) | 2004-12-30 | 2012-02-21 | Lifesensors, Inc. | Human SUMO-3 for enhancing protein expression |
| EP2059253A4 (en) | 2006-09-14 | 2011-09-14 | Univ Pennsylvania | MODULATION OF T LYMPHOCYTES REGULATORS BY HUMAN IL-18 |
| AU2007342011A1 (en) | 2006-12-29 | 2008-07-10 | Lifesensors, Inc. | Methods and compositions for enhanced protein expression and purification |
| WO2009062102A2 (en) | 2007-11-07 | 2009-05-14 | Genentech, Inc. | Compositions and methods for treatment of microbial disorders |
| CN101960209B (zh) | 2008-02-27 | 2012-11-07 | 夏普株式会社 | 照明装置、显示装置和电视接收装置 |
| US8034910B2 (en) | 2008-05-06 | 2011-10-11 | Academia Sinica, Taiwan | SUMO fusion protein expression system for producing native proteins |
| CN101993495B (zh) | 2009-08-12 | 2013-07-24 | 上海近岸科技有限公司 | 一种蛋白质混合物及其制备方法 |
| US9316417B2 (en) | 2012-06-29 | 2016-04-19 | Sunpower Corporation | Framing system for mounting solar collecting devices |
| BR112015002091A2 (pt) | 2012-08-02 | 2017-12-12 | Hoffmann La Roche | método para a produção de um polipeptídeo, polipeptídeo, uso de um polipeptídeo e composição |
| US9376489B2 (en) * | 2012-09-07 | 2016-06-28 | Novartis Ag | IL-18 binding molecules |
| US10646548B2 (en) | 2013-10-08 | 2020-05-12 | Georgia State University Research Foundation, Inc. | Compositions including IL-18 and IL-22 and their use in anti-viral therapies |
| US10882905B2 (en) | 2015-03-05 | 2021-01-05 | Ab2 Bio Sa | IL-18 binding protein (IL-18BP) and antibodies in inflammatory diseases |
| RU2749113C2 (ru) | 2015-04-22 | 2021-06-04 | Куревак Аг | Содержащая рнк композиция для лечения опухолевых заболеваний |
| WO2017102010A1 (en) * | 2015-12-17 | 2017-06-22 | Biontech Rna Pharmaceuticals Gmbh | Novel cytokine fusion proteins |
| CA3011374A1 (en) | 2016-02-05 | 2017-08-10 | Washington University | Compositions and methods for targeted cytokine delivery |
| WO2017165464A1 (en) | 2016-03-21 | 2017-09-28 | Elstar Therapeutics, Inc. | Multispecific and multifunctional molecules and uses thereof |
| ITUA20161992A1 (it) | 2016-03-24 | 2017-09-24 | Plico Biotech Inc | Sumo e suoi utilizzi |
| AU2017305524B2 (en) | 2016-08-04 | 2024-09-26 | Memorial Sloan-Kettering Cancer Center | Compositions and methods for immunotherapy |
| JP2019529499A (ja) | 2016-09-30 | 2019-10-17 | ベイラー カレッジ オブ メディスンＢａｙｌｏｒ Ｃｏｌｌｅｇｅ Ｏｆ Ｍｅｄｉｃｉｎｅ | 組織指向性発現を用いた抗体ベースの遺伝子治療 |
| TWI591177B (zh) | 2016-10-27 | 2017-07-11 | 中化合成生技股份有限公司 | 一種胰高血糖素胜肽－２（ｇｌｐ－２）類似物的製備方法 |
| CN117986384A (zh) | 2017-03-06 | 2024-05-07 | 艾尔特生物科技公司 | 与il-12和il-18的基于il-15的融合物 |
| US20210017247A1 (en) | 2017-07-03 | 2021-01-21 | Torque Therapeutics, Inc. | Fusion Molecules Targeting Immune Regulatory Cells and Uses Thereof |
| EP3788150A4 (en) | 2018-05-04 | 2022-01-26 | Sigma-Aldrich Co. LLC | PRODUCTION OF RECOMBINANT PROTEINS WITH REDUCED LEVELS OF HOST CELL PROTEINS |
| US11518792B2 (en) | 2018-08-30 | 2022-12-06 | HCW Biologics, Inc. | Multi-chain chimeric polypeptides and uses thereof |
| CA3109361A1 (en) | 2018-08-30 | 2020-03-05 | HCW Biologics, Inc. | Single-chain and multi-chain chimeric polypeptides and uses thereof |
| US11401324B2 (en) | 2018-08-30 | 2022-08-02 | HCW Biologics, Inc. | Single-chain chimeric polypeptides and uses thereof |
| KR20210127924A (ko) | 2019-01-04 | 2021-10-25 | 레퍼토리 아임뮨 메디신스, 인크. | 고다양성 펩티드 라이브러리의 제조 및 단백질 폴딩의 촉진 방법 |
| KR20220023988A (ko) | 2019-05-14 | 2022-03-03 | 웨어울프 세라퓨틱스, 인크. | 분리 모이어티 및 이의 사용 방법 |
| US20220226464A1 (en) | 2019-05-28 | 2022-07-21 | Massachusetts Institute Of Technology | Methods and compositions for modulating immune responses |
| WO2020243729A1 (en) | 2019-05-31 | 2020-12-03 | Children's National Medical Center | Cytokine cocktails for selective expansion of t cell subsets |
| EP4013857A1 (en) | 2019-08-13 | 2022-06-22 | King's College London | Immunoresponsive cells armoured with spatiotemporally restricted activity of cytokines of the il-1 superfamily |
| WO2021072211A1 (en) | 2019-10-09 | 2021-04-15 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating cytotoxic t cell resistant tumors |
| KR20230084470A (ko) | 2020-08-14 | 2023-06-13 | 카이트 파마 인코포레이티드 | 면역 세포 기능의 향상 |
| WO2022038417A2 (en) | 2020-08-19 | 2022-02-24 | Bright Peak Therapeutics Ag | Modified il-18 polypeptides and uses thereof |
| TW202233657A (zh) | 2020-11-02 | 2022-09-01 | 美商辛卡Ｉｌ １８公司 | 介白素-18變體及使用方法 |
| KR20240007179A (ko) | 2021-04-30 | 2024-01-16 | 셀렉티스 에스.에이. | 고형 종양 암 면역 요법을 위한 새로운 항-muc1 car 및 유전자 편집된 면역세포 |
| WO2022260968A1 (en) | 2021-06-10 | 2022-12-15 | Chimera Bioengineering, Inc. | Compositions and methods for activating natural killer cells |
-
2018
- 2018-09-06 CN CN201880071694.4A patent/CN111315395A/zh active Pending
- 2018-09-06 EP EP18853870.6A patent/EP3678681A4/en active Pending
- 2018-09-06 MX MX2020002542A patent/MX2020002542A/es unknown
- 2018-09-06 JP JP2020513648A patent/JP7795181B2/ja active Active
- 2018-09-06 AU AU2018330444A patent/AU2018330444B2/en active Active
- 2018-09-06 CA CA3080492A patent/CA3080492A1/en active Pending
- 2018-09-06 BR BR112020004389-3A patent/BR112020004389A2/pt unknown
- 2018-09-06 WO PCT/US2018/049648 patent/WO2019051015A1/en not_active Ceased
- 2018-09-06 US US16/123,063 patent/US20190070262A1/en not_active Abandoned
- 2018-09-06 SG SG11202001384TA patent/SG11202001384TA/en unknown
- 2018-09-06 IL IL305370A patent/IL305370A/en unknown
- 2018-09-06 KR KR1020207009724A patent/KR20200066623A/ko not_active Ceased
- 2018-09-06 IL IL272635A patent/IL272635B2/en unknown
-
2022
- 2022-11-15 US US18/055,581 patent/US12343379B2/en active Active
-
2023
- 2023-01-20 US US18/157,385 patent/US20230321192A1/en active Pending
- 2023-03-08 US US18/180,389 patent/US12403180B2/en active Active
- 2023-07-19 ZA ZA2023/07212A patent/ZA202307212B/en unknown
- 2023-08-18 JP JP2023133442A patent/JP2023157959A/ja active Pending
- 2023-11-15 AU AU2023266285A patent/AU2023266285A1/en not_active Abandoned
-
2024
- 2024-04-04 US US18/626,930 patent/US20240325494A1/en active Pending
- 2024-11-08 US US18/941,441 patent/US12594325B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA3080492A1 (en) | 2019-03-14 |
| JP7795181B2 (ja) | 2026-01-07 |
| BR112020004389A2 (pt) | 2020-09-08 |
| EP3678681A4 (en) | 2021-07-14 |
| IL272635B2 (en) | 2024-02-01 |
| US12403180B2 (en) | 2025-09-02 |
| WO2019051015A1 (en) | 2019-03-14 |
| US20230241172A1 (en) | 2023-08-03 |
| US20230321192A1 (en) | 2023-10-12 |
| KR20200066623A (ko) | 2020-06-10 |
| JP2020533301A (ja) | 2020-11-19 |
| US20230355714A1 (en) | 2023-11-09 |
| US12343379B2 (en) | 2025-07-01 |
| US20190070262A1 (en) | 2019-03-07 |
| IL272635B1 (en) | 2023-10-01 |
| JP2023157959A (ja) | 2023-10-26 |
| AU2023266285A1 (en) | 2024-01-25 |
| CN111315395A (zh) | 2020-06-19 |
| AU2018330444A1 (en) | 2020-04-23 |
| AU2018330444B2 (en) | 2023-08-17 |
| IL272635A (en) | 2020-03-31 |
| US12594325B2 (en) | 2026-04-07 |
| IL305370A (en) | 2023-10-01 |
| US20250057918A1 (en) | 2025-02-20 |
| EP3678681A1 (en) | 2020-07-15 |
| US20240325494A1 (en) | 2024-10-03 |
| SG11202001384TA (en) | 2020-03-30 |
| RU2020112538A3 (https=) | 2022-04-04 |
| MX2020002542A (es) | 2020-07-20 |
| RU2020112538A (ru) | 2021-10-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202307212B (en) | Interleukin-18 variants and methods of use | |
| ZA201906822B (en) | Indole ahr inhibitors and uses thereof | |
| ZA201905488B (en) | Tigit- and light-based chimeric proteins | |
| MX2021014441A (es) | Inhibidores del dominio asociado mejorador de la transcripcion (tead) y usos de los mismos. | |
| SA520411202B1 (ar) | مترافقات سيتوكين لعلاج أمراض المناعة الذاتية | |
| PH12021500026A1 (en) | Irak degraders and uses thereof | |
| MX2022004304A (es) | Agentes inductores de apoptosis. | |
| PH12017501483A1 (en) | Bicyclic heterocycles as fgfr4 inhibitors | |
| MX2020001793A (es) | Inhibidores del receptor de hidrocarburos de arilo (ahr) y usos de los mismos. | |
| MX2023011657A (es) | Composiciones que comprenden curones y usos de los mismos. | |
| BR112019017403A2 (pt) | composições e métodos para o tratamento de câncer | |
| MX2021001186A (es) | Purinonas como inhibidores de proteasa especifica de ubiquitina 1. | |
| MX2016003843A (es) | Inhibidores de cinasas asociadas al receptor de interleucina 1 (irak) y usos de los mismos. | |
| MX2018005292A (es) | Inhibidores de acc y usos de los mismos. | |
| PH12016501107B1 (en) | Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology | |
| PH12017501669A1 (en) | Alpha-cinnamide compounds and compositions as hdac8 inhibitors | |
| CR20180029A (es) | Inhibidores peotídicos del receptor de interleucina 23 y su uso para tratar enfermedades inflamatorias | |
| PH12018500408A1 (en) | Bicyclic compounds as atx inhibitors | |
| ECSP14013148A (es) | Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak | |
| MX2018007304A (es) | Composiciones de interleucina-15 y sus usos. | |
| MX2019010984A (es) | Composiciones de sintecina y metodos de uso. | |
| PH12018501279A1 (en) | Compositions comprising 15-hepe and methods of using the same | |
| WO2018226992A8 (en) | Tau aggregation inhibitors | |
| MX2019002185A (es) | Composiciones y metodos relacionados con la inhibicion de la señalizacion de rangos. | |
| ZA202000354B (en) | Novel braf inhibitors and use thereof for treatment of cutaneous reactions |